Identification of the cathelicidin peptide LL-37 as agonist for the type i insulin-like growth factor receptor

Oncogene

Volumn 31, Issue 3, 2012, Pages 352-365

  Girnita, A ^a,b   Zheng, H ^a   Gronberg A ^b   Girnita, L ^a   Sthle, M ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

breast cancer; IGF 1R; invasion; LL 37; metastasis

Indexed keywords

BETA ARRESTIN; BETA ARRESTIN 1; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C;

ARTICLE; BINDING AFFINITY; CELL MIGRATION; CELL PROLIFERATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; UBIQUITINATION;

ANTIMICROBIAL CATIONIC PEPTIDES; ARRESTINS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; UBIQUITINATION;

EID: 84855968882     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.239     Document Type: Article

References (60)

1. Adams TE, Epa VC, Garrett TP, Ward CW. (2000). Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57: 1050-1093. (Pubitemid 30598754)
2. Ahn S, Nelson CD, Garrison TR, Miller WE, Lefkowitz RJ. (2003). Desensitization, internalization, and signaling functions of betaarrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 100: 1740-1744. (Pubitemid 36254518)
3. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. (2002). Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 43: 1-8. (Pubitemid 34032432)
4. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM et al. (1992). Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem 267: 17882-17890.
5. Balkwill F, Mantovani A. (2001). Inflammation and cancer: back to Virchow? Lancet 357: 539-545. (Pubitemid 32173595)
6. Barlow PG, Li Y, Wilkinson TS, Bowdish DM, Lau YE, Cosseau C et al. (2006). The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J Leukoc Biol 80: 509-520. (Pubitemid 44835784)
7. Baserga R. (2000). The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19: 5574-5581.
8. Baserga R. (2005). The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9: 753-768. (Pubitemid 41131677)
9. Baserga R. (2009). The insulin receptor substrate-1: a biomarker for cancer? Exp Cell Res 315: 727-732.
10. Baserga R, Peruzzi F, Reiss K. (2003). The IGF-1 receptor in cancer biology. Int J Cancer 107: 873-877. (Pubitemid 37429826)
11. hamorro CI, Weber G, Gronberg A, Pivarcsi A, Stahle M. (2009). The human antimicrobial peptide LL-37 suppresses apoptosis in keratinocytes. J Invest Dermatol 129: 937-944.
12. Clemmons DR. (2007). Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6: 821-833. (Pubitemid 47500506)
13. Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL et al. (2009). The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci USA 106: 3806-3811.
14. Coffelt SB, Scandurro AB. (2008). Tumors sound the alarmin(s). Cancer Res 68: 6482-6485.
15. Coffelt SB, Waterman RS, Florez L, Honer zu Bentrup K, Zwezdaryk KJ, Tomchuck SL et al. (2008). Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer 122: 1030-1039. (Pubitemid 351214000)
16. Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature 420: 860-867. (Pubitemid 36019639)
17. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J et al. (2000). LL-37, the neutrophil granule-and epithelial cellderived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192: 1069-1074.
18. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. (2007). Beta-arrestins and cell signaling. Annu Rev Physiol 69: 483-510.
19. Dews M, Prisco M, Peruzzi F, Romano G, Morrione A, Baserga R. (2000). Domains of the insulin-like growth factor I receptor required for the activation of extracellular signal-regulated kinases. Endocrinology 141: 1289-1300. (Pubitemid 32269095)
20. Doerr ME, Jones JI. (1996). The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 271: 2443-2447.
21. Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B, Steenbergh PH et al. (1997). Mitogenic signaling of insulinlike growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogenactivated protein kinase. J Biol Chem 272: 31163-31171. (Pubitemid 27527567)
22. Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R et al. (1998). A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58: 3353-3361. (Pubitemid 28371076)
23. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC. (2001). Upregulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 61: 1367-1374. (Pubitemid 34292558)
24. Elssner A, Duncan M, Gavrilin M, Wewers MD. (2004). A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 172: 4987-4994. (Pubitemid 38456425)
25. Gennaro R, Zanetti M. (2000). Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 55: 31-49.
26. Girnita A, All-Ericsson C, Economou MA, Astrom K, Axelson M, Seregard S et al. (2006). The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 12: 1383-1391. (Pubitemid 43342532)
27. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. (2004). Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64: 236-242. (Pubitemid 38114104)
28. Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, Dricu A et al. (2000a). Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 60: 5278-5283.
29. Girnita L, Girnita A, Larsson O. (2003). Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 100: 8247-8252. (Pubitemid 36842530)
30. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, Lefkowitz RJ et al. (2005). {beta}-Arrestin is crucial for ubiquitination and downregulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem 280: 24412-24419. (Pubitemid 40934525)
31. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A et al. (2007). Beta-arrestin and Mdm2 mediate IGF-1 receptorstimulated ERK activation and cell cycle progression. J Biol Chem 282: 11329-11338. (Pubitemid 47100796)
32. Girnita L, Wang M, Xie Y, Nilsson G, Dricu A, Wejde J et al. (2000b). Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. Anticancer Drug Des 15: 67-72. (Pubitemid 30364900)
33. Heilborn JD, Nilsson MF, Jimenez CI, Sandstedt B, Borregaard N, Tham E et al. (2005). Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer 114: 713-719. (Pubitemid 40344432)
34. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N et al. (2003). The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 120: 379-389. (Pubitemid 36298423)
35. Hubbard SR, Miller WT. (2007). Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol 19: 117-123. (Pubitemid 46386407)
36. Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T et al. (2003). An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111: 1665-1672. (Pubitemid 38057748)
37. Larsson O, Girnita A, Girnita L. (2005). Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92: 2097-2101. (Pubitemid 40966242)
38. LeRoith D, Roberts Jr CT. (2003). The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137. (Pubitemid 36588961)
39. Mader JS, Hoskin DW. (2006). Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 15: 933-946. (Pubitemid 44177845)
40. Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O et al. (2006). Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107: 655-660. (Pubitemid 43076391)
41. Natalishvili N, Axelson M, Girnita L, Larsson O, Vasilcanu D. (2009). Aberrant intracellular IGF-1R beta-subunit makes receptor knockout cells (IGF1R-/-) susceptible to oncogenic transformation. Exp Cell Res 315: 1458-1467.
42. Pollak M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
43. Radek K, Gallo R. (2007). Antimicrobial peptides: natural effectors of the innate immune system. Semin Immunopathol 29: 27-43. (Pubitemid 47596388)
44. Rajagopal S, Rajagopal K, Lefkowitz RJ. (2010). Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9: 373-386.
45. Razuvaev A, Henderson B, Girnita L, Larsson O, Axelson M, Hedin U et al. (2007). The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg 46: 108-115. (Pubitemid 46990746)
46. Samani AA, Yakar S, LeRoith D, Brodt P. (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20-47. (Pubitemid 46220849)
47. Sehat B, Andersson S, Girnita L, Larsson O. (2008). Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 68: 5669-5677.
48. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T et al. (1994). Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14: 3604-3612. (Pubitemid 24160768)
49. Shaykhiev R, Behr J, Bals R. (2008). Microbial patterns signaling via Toll-like receptors 2 and 5 contribute to epithelial repair, growth and survival. PLoS One 3: e1393.
50. Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sorensen OE, Borregaard N et al. (2003). The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 171: 6690-6696. (Pubitemid 37532101)
51. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y et al. (2005). Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol 175: 4662-4668. (Pubitemid 41362007)
52. Tornkvist M, Natalishvili N, Xie Y, Girnita A, D'Arcy P, Brodin B et al. (2008). Differential roles of SS18-SSX fusion gene and insulinlike growth factor-1 receptor in synovial sarcoma cell growth. Biochem Biophys Res Commun 368: 793-800.
53. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. (1998). Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42: 2206-2214. (Pubitemid 28420351)
54. Ulfarsson E, Karstrom A, Yin S, Girnita A, Vasilcanu D, Thoren M et al. (2005). Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin Cancer Res 11: 4674-4680. (Pubitemid 41557184)
55. Vasilcanu R, Vasilcanu D, Sehat B, Yin S, Girnita A, Axelson M et al. (2008). Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol Pharmacol 73: 930-939. (Pubitemid 351397897)
56. Violin JD, Lefkowitz RJ. (2007). Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28: 416-422.
57. von Haussen J, Koczulla R, Shaykhiev R, Herr C, Pinkenburg O, Reimer D et al. (2008). The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer 59: 12-23.
58. Weber G, Chamorro CI, Granath F, Liljegren A, Zreika S, Saidak Z et al. (2009). Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res 11: R6.
59. Yin SC, Girnita A, Stromberg T, Khan Z, Andersson S, Zheng HY et al. (2010). Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro-Oncology 12: 19-27.
60. Zanetti M. (2004). Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 75: 39-48. (Pubitemid 38166778)